drugset / Trial / NCT00003489

Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer

NCT00003489

Phase 2 Terminated 7 enrolled Burzynski Research Institute
NaSingle-groupOpen-labelTreatment

Summary

Current therapies for advanced Head and Neck Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Head and Neck Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with advanced Head and Neck Cancer.

Timeline

Start
1996-05-06
Primary completion
1998-04-03
Completion
1998-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Astugenal Unknown Intravenous
Subject antineoplaston A10 Small molecule Intravenous

Indications